Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: Implications for resistance mutations and inhibitor design

R. A. Powers, E. Caselli, P. J. Focia, F. Prati, B. K. Shoichet*

*Corresponding author for this work

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Third-generation cephalosporins are widely used β-lactam antibiotics that resist hydrolysis by β-lactamases. Recently, mutant β-lactamases that rapidly inactivate these drugs have emerged. To investigate why third-generation cephalosporins are relatively stable to wild-type class C β-lactamases and how mutant enzymes might overcome this, the structures of the class C β-lactamase AmpC in complex with the third-generation cephalosporin ceftazidime and with a transition-state analogue of ceftazidime were determined by X-ray crystallography to 2.0 and 2.3 Å resolution, respectively. Comparison of the acyl-enzyme structures of ceftazidime and loracarbef, a β-lactam substrate, reveals that the conformation of ceftazidime in the active site differs from that of substrates. Comparison of the structures of the acyl-enzyme intermediate and the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transition state, explaining why it is an inhibitor of AmpC. Ceftazidime cannot adopt a conformation competent for catalysis due to steric clashes that would occur with conserved residues Va1211 and Tyr221. The X-ray crystal structure of the mutant β-lactamase GC1, which has improved activity against third-generation cephalosporins, suggests that a tandem tripeptide insertion in the Ω loop, which contains Va1211, has caused a shift of this residue and also of Tyr221 that would allow ceftazidime and other third-generation cephalosporins to adopt a more catalytically competent conformation. These structural differences may explain the extended spectrum activity of GC1 against this class of cephalosporins. In addition, the complexed structure of the transition-state analogue inhibitor (Ki 20 nM) with AmpC reveals potential opportunities for further inhibitor design.

Original languageEnglish (US)
Pages (from-to)9207-9214
Number of pages8
JournalBiochemistry
Volume40
Issue number31
DOIs
StatePublished - Aug 7 2001

ASJC Scopus subject areas

  • Biochemistry

Fingerprint Dive into the research topics of 'Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: Implications for resistance mutations and inhibitor design'. Together they form a unique fingerprint.

  • Cite this